Pemigatinib-induced nail changes - A case report

Authors

Nicolle A. Trudeau, Advocate Aurora HealthFollow
Jessica M. Lawton, Advocate Aurora HealthFollow
Nirav D. Patel, Advocate Aurora HealthFollow

Recommended Citation

Trudeau NA, Lawton JM, Patel ND. Pemigatinib-induced nail changes - A case report. J Oncol Pharm Pract. 2021;27(7):1795-1798. doi:10.1177/10781552211002629

Affiliations

Aurora BayCare Medical Center

Abstract

INTRODUCTION: Pemigatinib is an FGFR inhibitor that is one of few second-line treatment options for cholangiocarcinoma. Nail toxicities were common in the phase 2 study evaluating the safety and efficacy of pemigatinib.

CASE REPORT: We describe a 54-year-old female with a history of stage IV cholangiocarcinoma presenting for a follow-up visit after completing Cycle 4 of pemigatinib. The patient had been having significant nail changes to her fingernails and toenails, which has led to her great toenails falling off.

DISCUSSION: Nail changes are a common side effect with pemigatinib and should be monitored closely for the need for temporary disruption in therapy.

Document Type

Case Report

PubMed ID

33736556